Imunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole.
The effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) administered separately or with anthelmintic albendazole (ABZ) on cellular immunity of mice with alveolar echinococcosis was studied. The proliferative activity of splenic T and B lymphocytes was the most stimulated after combined L-MTP-PE + ABZ therapy [from weeks 8 to 14 post-infection (p.i.)] that also induced a long-term development of protective Th1 response (the highest serum concentration of IFN-gamma from weeks 8 to 18 p.i.). On the contrary, Th2 response (cytokine IL-5) in infected mice treated with L-MTP-PE was inhibited since week 8 p.i., but a significant long-term decrease in IL-5 concentration was found after combined L-MTP-PE+ABZ therapy until the end of the experiment (until week 26 p.i.). L-MTP-PE stimulated the production of superoxide anion (O2-) by peritoneal macrophages from weeks 8 to 12 p.i., but the highest O2- production was accordingly recorded after therapy L-MTP-PE+ABZ from weeks 8 to 18 p.i. Stimulation of cellular immunity of mice with alveolar echinococcis with L-MTP-PE and an interaction with ABZ's anti-parasitic effect resulted in the greatest and long-term reduction of growth of Echinococcus multilocularis cysts in the host from week 10 p.i. until the end of the experiment.
Dvoroznáková
Emília
E
Parasitological Institute of the Slovak Academy of Sciences, Hlinkova 3, 040 01 Kosice, Slovak Republic. dvoroz@saske.sk
Porubcová
Jarmila
J
Snábel
Viliam
V
Fedorocko
Peter
P
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D015766:Albendazole / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000871:Anthelmintics / Q000494:pharmacology / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology; D002478:Cells, Cultured; D004444:Echinococcosis, Hepatic / Q000188:drug therapy*; D048210:Echinococcus multilocularis / Q000302:isolation & purification*; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000097:blood; D015848:Interleukin-5 / Q000097:blood; D008081:Liposomes / Q000494:pharmacology / Q000627:therapeutic use*; D017737:Macrophages, Peritoneal / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010714:Phosphatidylethanolamines / Q000494:pharmacology / Q000627:therapeutic use*; D013154:Spleen / Q000276:immunology; D013481:Superoxides / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology
D000871:Anthelmintics; D007155:Immunologic Factors; D015848:Interleukin-5; D008081:Liposomes; D010714:Phosphatidylethanolamines; D013481:Superoxides; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D007371:Interferon-gamma; D015766:Albendazole